Abbott Laboratories (NYSE: ABT) is a large market cap stock with a market cap of 77.16B. It is in the Medical Appliances & Equipment industry and sector Healthcare, with a current P/E of 49.58, a forward P/E of 16.16 and EPS of 0.9. At a stock price of 44.43 (-0.54%) it has a dividend yield of 2.37%.
EPS growth for the last five years have been 0.00%, more recently this last year it has grown by -58.60%. The next year growth is going to be about 11.90% and more long-term 11.22% after five years. EPS growth quarter over quarter is 489.40%. Sales growth for the past five years have been -0.50% and sales growth quarter over quarter is 29.70%.
For performance, Abbott Laboratories the past week has seen a gain of 2.45%. For the last month performance for Abbott Laboratories is 2.54%. While the last quarter is 4.79% and half year, 15.72%. Finally for the year, performance is 20.59%.
The 52-week high for Abbott Laboratories, is at -2.48%, and for the 52-week low it comes to a value of 23.93%. The 20-day simple moving average is 1.45% and 6.53% for the 200-day simple moving average.
Volatility for the week is at 0.83%, and for the month it is 1.13%. Abbott Laboratories, has a target price of 48.27.
In terms of debt, long term debt/equity is 0.76, and for total debt/equity Abbott Laboratories has 0. The gross margin is 55.50%, while operating margin is 11.00%, the profit margin is 6.70%. The current ratio is 2.9 and the quick ratio is 2.3.
Insider ownership is at 0.70%, with instituitional ownership at 66.40%. Abbott Laboratories has a payout ratio of 107.00%. With the total shares outstanding coming to 1727.36. The shares float is 1715.43, with the float short at 0.81%, with short ratio coming to 2.
In terms of returns, the return on assets see Abbott Laboratories, get 3.00%, with its returns on investment at 6.70%. Return on equity is 6.40%. So will the investors see the target price of 48.27, reached soon?
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.
Abbott Laboratories (NYSE: ABT)
This post was originally published on *this site*